SCHEMBL1285848

SCHEMBL1285848

CC1(C(=O)O)C=CCCC1

nearest known ligand 0.37

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
FFAR3 O14843 1/20 0.37
CYP3A4 P08684 1/20 0.33
CCR2 P41597 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29955880 1.00 FFAR3 (0.37) FFAR3CYP3A4CCR2
SCHEMBL17694227 0.92 FFAR3 (0.34) FFAR3CYP3A4
SCHEMBL8356300 0.86
SCHEMBL7355905 0.81 PKM (0.31)
SCHEMBL27773646 0.79
SCHEMBL2124042 0.78 CYP3A4 (0.38) CYP3A4
SCHEMBL4382364 0.77
SCHEMBL17696543 0.75 CYP3A4 (0.33) CYP3A4
SCHEMBL28078294 0.74
SCHEMBL27800390 0.74 SMN1; SMN2 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10072043-B2 Inhibitors of protein tyrosine phosphatases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2018-09-11 US claimed
US-20160176922-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES Indiana University Research and Technology Corpora tion (US) 2016-06-23 US claimed
US-9217012-B2 Inhibitors of protein tyrosine phosphatases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2015-12-22 US claimed
US-20120088720-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATI (US) 2012-04-12 US claimed
WO-2010118241-A2 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) 2010-10-14 WO claimed
US-7732625-B2 Colorant compounds XEROX CORPORATION (US) 2010-06-08 US claimed
US-7311767-B2 Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens XEROX CORPORATION (US) 2007-12-25 US claimed
US-7033424-B2 Phase change inks XEROX CORPORATION (US) 2006-04-25 US claimed
US-20060021546-A1 Processes for preparing phase change inks XEROX CORPORATION 2006-02-02 US claimed
US-20060020141-A1 Metallized dye XEROX CORPORATION 2006-01-26 US claimed
US-20060016369-A1 PHASE CHANGE INKS XEROX CORPORATION 2006-01-26 US claimed
US-6946025-B2 Process for preparing tetra-amide compounds XEROX CORPORATION (US) 2005-09-20 US claimed
US-20050090690-A1 Process for preparing tetra-amide compounds XEROX CORPORATION 2005-04-28 US claimed
US-12551555-B2 Compositions and methods for potentiating immune activity KUMQUAT BIOSCIENCES INC. (US) 2026-02-17 US disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
CN-115103907-A Compositions and methods for enhancing immune activity 金橘生物科技公司 2022-09-23 CN disclosed
EP-1091958-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2001-04-18 EP disclosed
WO-2000001692-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2000-01-13 WO disclosed
EP-0831918-A2 DRUG MITOCHONDRIAL TARGETING AGENTS TRUSTEES OF BOSTON UNIVERSITY (US) 1998-04-01 EP disclosed
WO-1996039193-A2 DRUG MITOCHONDRIAL TARGETING AGENTS TRUSTEES OF BOSTON UNIVERSITY (US) 1996-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10072043-B2 Inhibitors of protein tyrosine phosphatases PTPRCAP, PTPRF, PTPRS FFAR3 4790/4885CYP3A4 4051/4885CCR2 3102/4885
US-12551555-B2 Compositions and methods for potentiating immune activity PTPRCAP, PTPN2, PTPRC FFAR3 2958/4885CYP3A4 3794/4885CCR2 479/4885
US-20160176922-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES PTPRCAP, PTPRF, PTPRS FFAR3 4790/4885CYP3A4 4051/4885CCR2 3102/4885
US-20060020141-A1 Metallized dye CDYL, CDY1; CDY1B, CDYL2 FFAR3 3784/4885CYP3A4 797/4885CCR2 863/4885
US-20050090690-A1 Process for preparing tetra-amide compounds TAF9, TAF5, TAF1 FFAR3 2987/4885CYP3A4 548/4885CCR2 3795/4885
US-20120088720-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES PTPRCAP, PTPRF, PTPRS FFAR3 4790/4885CYP3A4 4051/4885CCR2 3102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.